Epidemiological trends of invasive Streptococcus pyogenes infections in Catalonia, 2022–2024: a two-year analysis Authors: Marta Martorell, Aurora Sabrià, Victoria Rello-Saltor, Antoni Soriano-Arandes, Damaris Berbel, Cristina Esteva, M Dolors Estivill, Silvia Capilla, Teresa Llovet, Inés Valle, F Xavier Queralt, Mireia Rajadell, M Dolores Quesada, Maria Navarro, Frederic Gomez-Bertomeu, Yuliya Poliakova, Alba Bellés, Laura Solaz, Ana Siverio, Guillem Vidal, Mar Olga Perez-Moreno, Claudia Miralles, Elisabet Folch, Natàlia Roca, Mariana Fernandez-Pittol, Jordi Duran, Pep Ballester, Carme Gallés, Belén Viñado, Sonia Broner, Jacobo Mendioroz, Pilar Ciruela Published: 2026 ABSTRACT AbstractObjectivesInvasive group A streptococcal (iGAS) infections resurged across Europe in late 2022. We aimed to describe the incidence, clinical characteristics, and outcomes of iGAS in Catalonia over two epidemic seasons (2022/23 and 2023/24), and to identify risk factors associated with mortality.MethodsA prospective study was conducted including all confirmed iGAS cases reported to the Microbiological Reporting System of Catalonia between October 2022 and October 2024. Epidemiological and clinical data were collected from medical files and incidence rates (IRs) calculated. Multivariable logistic regression was used to assess risk factors associated with mortality.ResultsA total of 589 laboratory-confirmed iGAS cases were included; 416 cases (70.6%) from 2022/23 season, and 173 (29.4%) from 2023/24. The overall IR decreased from 5.3 to 2.2 cases per 100,000 population (p < 0.001). In 2022/23, incidence was higher in children (0–14 years) than in adults (9.8 vs. 4.6 per 100,000; p < 0.001), whereas this pattern reversed in 2023/24 (1.7 vs. 2.3; p = 0.028). Pleural empyema predominated in children, while skin and soft tissue infections with bacteraemia in adults. Respiratory viral coinfections were more common in children than in adults (47.1% vs. 10.8%; p < 0.001). Overall, 97.3% of patients were hospitalized, and 26.9% required intensive care (33.3% in children vs. 25.2% in adults; p = 0.08). Overall mortality was 11.3% (12.9% in adults and 5.8% in children: p < 0.05). Multivariable analyses showed age, respiratory viral coinfections, chronic renal disease, and intensive care unit admission independently associated with mortality.ConclusionsThe decline in iGAS incidence in 2023/24 was accompanied by a shift in age distribution and a reduction in respiratory viral coinfections, suggesting a return toward pre-pandemic epidemiological patterns. Further research is needed to clarify pathogenic mechanisms and outcome determinants.Supplementary InformationThe online version contains supplementary material available at 10.1007/s15010-026-02835-6.Keywords: Streptococcus pyogenes, Group A Streptococcus, Invasive GAS (iGAS), Invasive infections, Epidemiology Introduction Streptococcus pyogenes, or Group A Streptococcus (GAS), is a Gram-positive bacterium primarily transmitted through close contact with infected individuals. It is responsible for a wide spectrum of clinical manifestations, ranging from mild, superficial infections such as pharyngitis, scarlet fever and impetigo to severe, potentially lethal threatening invasive diseases. Invasive GAS (iGAS) is defined by the isolation of S. pyogenes from a normally sterile body site and is associated with significant morbidity and high case fatality rates [1]. The incidence of iGAS is highest among young children and older adults and several underlying conditions have been identified as risk factors, including diabetes, cancer, cardiovascular disease, immunosuppression, chronic lung or renal disease and previous surgery or postpartum status [1, 2]. Viral coinfections such as influenza A or varicella have also been described as risk factors for the development of iGAS disease [3, 4]. In autumn 2022, several European countries reported an unexpected increase of iGAS cases, with children under 10 years of age being the most affected age group [5]. In response, the World Health Organization issued an alert calling for enhance surveillance and close epidemiological monitoring [6]. Since then, multiple reports have documented an increase in iGAS notifications across Europe, extending from late 2022 through the first half of 2023 [7–12]. The reasons for this upsurge remains partially understood but likely reflects a combinations of factors, including increased susceptibility following reduced GAS circulation during the COVID-19 pandemic, circulation of other respiratory viruses and the emergence of more virulent GAS lineages [13]. In Catalonia, iGAS was not been subject to mandatory notification, except in cases of meningitis. However, in October 2022, enhanced surveillance was implemented requiring laboratories participating in the Microbiological Reporting System of Catalonia to report all laboratory-confirmed cases. Moreover, clinicians were required to notify cases to territorial epidemiological surveillance units, which were responsible for contact tracing and assessing the need for antibiotic prophylaxis in high-risk contacts. The objective of this study was to describe the incidence, clinical characteristics, and outcomes of laboratory-confirmed iGAS cases in Catalonia between October 2022 and September 2024. Additionally, we aimed to assess seasonal and age groups differences in incidence and to identify factors associated with iGAS-related mortality. Methods This study included all laboratory-confirmed iGAS cases reported to the Microbiological Reporting System of Catalonia) between 24 October 2022 and 19 October 2024. All cases fulfilled the definition of a confirmed invasive infection, with Streptococcus pyogenes isolated by culture or detected by nucleic acid testing from a normally sterile site. Sterile sites included, but were not limited to, blood, cerebrospinal fluid, joint fluid, pleural fluid, peritoneal fluid, bone, muscle, and internal organs. Each patient was included only once per illness episode, defined as occurring within 30 days of the initial positive test. Following laboratory reporting of confirmed invasive S. pyogenes cases to the Microbiological Reporting System of Catalonia, patients’ epidemiological and clinical data were retrospectively extracted from electronic medical records. Data covered the period from case detection to 1 month thereafter. Collected variables included sex, age, clinical presentation, risk factors for invasive disease, respiratory viral coinfections, and clinical outcomes. Clinical presentation was categorised as empyema, pneumonia with bacteraemia, primary bacteraemia, skin and soft tissue infection with bacteraemia, necrotizing fasciitis, mastoiditis, meningitis, septic arthritis, puerperal infections and others. Risk factors were classified according to a published article on standardization of epidemiological surveillance of iGAS [1]. These encompassed both clinical risk factors for invasive infection-such as diabetes, chronic heart disease, chronic renal disease, chronic pulmonary disease, immunosuppression, recent surgery or delivery within the previous 7 days -and clinical conditions which could serve as potential portal of entry- specifically acute or chronic skin lesion and pharyngitis or scarlet fever within the preceding 7 days. Immunosuppression was defined in this study as the presence of any of the following: chronic use of immunosuppressive drugs, active cancer or hematologic malignancy, HIV infection, or long-term corticosteroid therapy. Respiratory viral coinfections were defined as microbiologically confirmed respiratory viruses detected within 7 days of iGAS diagnosis. Data were retrospectively extracted from clinical records as a part of routine diagnostic practice. Testing for respiratory viruses was performed according to local protocols and clinician criteria and the frequency of testing could be not uniform across centres. Most tests were conducted using multiplex viral panels, although the specific panels differed across laboratories. Moreover, in some cases, it was not possible to determine whether respiratory viral testing had been performed. Consequently, a recorded absence of respiratory viral co-infection may reflect lack of testing rather than true absence of infection. Clinical outcomes analysed were hospitalization, intensive care unit (ICU) admission, and mortality. Mortality was defined as all-cause death within 30 days of iGAS diagnosis and expressed as the proportion of deaths among confirmed cases. For the analysis of seasonal trends, two epidemiological periods were defined: 2022/23 (week 43 of 2022 to week 42 of 2023) and 2023/24 (week 43 of 2023 to week 42 of 2024). For descriptive purposes, the population was categorized into the following age groups: <1 year, 1–4 years, 5–9 years, 10–14 years, 15–19 years, 20–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, 80–89 years, and ≥ 90 years. In addition, for analytical purposes, individuals were classified as paediatric (0–14 years) or adult (≥ 15 years). Incidence rates (IR) were calculated as cumulative incidence per 100,000 population, using population data from the Statistical Institute of Catalonia for the years 2022 and 2023 [14]. Incidence rate ratio (IRR) were used for comparisons. Quantitative variables were summarized as medians and interquartile ranges (IQR), while qualitative variables were expressed as absolute numbers and percentages. The Chi-squared test and Mann–Whitney U test were used for categorical and continuous variables, respectively. Binary logistic regression was used to identify risk factors associated with adverse clinical outcomes. Statistical significance was defined as a p < 0.05, and 95% confidence intervals (CI) were calculated for all estimates. Variables with a p < 0.20 in the univariate analysis were included in the multivariate model. Data were analysed using IBM SPSS Statistics version 24. Results A total of 589 laboratory-confirmed iGAS cases were reported to the Microbiological Reporting System of Catalonia during the study period. Of these, 416 cases (70.6%) occurred during the 2022/23 season, and 173 cases (29.4%) during 2023/24. The peak of notifications was observed between epidemiological weeks 52/2022 and 12/2023 (Fig. 1). Number of laboratory-confirmed invasive group A Streptococcal infections by week of diagnosis and season. Catalonia, October-2022-October 2024 The overall IR was 5.3 cases per 100,000 population in 2022/23 and 2.2 cases per 100,000 in 2023/24, representing a 2.4-fold reduction between seasons (IRR: 0.41; 95% CI: 0.34–0.49; p < 0.001). The decline was more pronounced in children aged 0–14 years (9.8 to 1.7 per 100,000; IRR 0.17; 95% CI: 0.10–0.26; p < 0.001) than in adults (4.6 to 2.3 per 100,000; IRR 0.50; 95% CI 0.41–0.62; p < 0.001). A more detailed age-specific analysis showed that during the 2022/23 season, the highest IRs were observed in infants < 1 year (28.7 cases per 100,000), children aged 1–4 years (23.5), and adults aged ≥ 90 years (15.4), followed by those aged 80–89 years (11.8) and 70–79 years (10.0). In 2023/24, incidence declined across all age groups, but the most pronounced reductions were observed among young children (Fig. 2). Number of cases and incidence rates of laboratory-confirmed invasive group A Streptococcal infections by group of age and season. Catalonia October 2022-October 2024. IR Incidence rate per 100,000 population All 589 cases were confirmed by isolation of Streptococcus pyogenes from one or more than one sterile-site specimens (547 [92.9%] from a single sterile site and 42 [7.1%] from multiple sterile sites). Isolates were obtained from blood (n = 469), pleural fluid (n = 65), synovial fluid (n = 37), cerebrospinal fluid (n = 6), and biopsies or intraoperative specimens (n = 41). Data completeness was high: information on clinical presentation was available for 566 cases (96.1%), coinfections for 545 (93.0%), risk factors for 551 (93.5%), hospitalization and ICU admission for 553 (93.9%), and mortality data for 556 cases (94.4%). Seasonal comparison Table 1 summarizes patient characteristics and clinical outcomes by season. Overall, a higher proportion of cases occurred in males, with no significant differences in sex distribution between the two seasons (55.3% men in 2022/23 vs. 58.3% in 2023/24; p = 0.55). The median age increased from 50.0 years (IQR: 11.2–73.2) in 2022/23 to 59.0 years (IQR: 38.3–76.3) in 2023/24 (p = 0.001). In 2022/23, 26.4% of cases occurred among children aged 0–14 years, compared to 11.0% in 2023/24 (p < 0.001). Pneumonia, with or without empyema, was the most frequent clinical presentation in 2022/23 (26.6%) but declined to 15.6% in 2023/24 (p = 0.03). In contrast, skin and soft tissue infections with bacteraemia became more prevalent in 2023/24 (32.9% vs. 20.4%; p < 0.01). Table 1Characteristics and outcomes of patients with laboratory-confirmed invasive group A Streptococcal infection by season. Catalonia, October-2022-October 20242022/23 season (n = 416) IR:5.32023/24 season (n = 173) IR: 2.2 p-valueSex Male230 (55.3%)101 (58.4%)0.55 Female186 (44.7%)72 (41.6%)Age (years)50.0 (11.2–73.2)59.0 (38.3–76.3)0.001Age group distribution 0–14 years110 (26.4%)19 (11.0%)< 0.001 ≥15 years306 (73.6%)154 (89.0%)< 0.001Clinical presentation Empyema68 (16.3%)10 (5.8%)< 0.001 Pneumonia with bacteraemia43 (10.3%)17 (9.8%)0.97 Primary bacteraemia86 (20.7%)39 (22.5%)0.70 Skin and soft tissue infection with bacteraemia85 (20.4%)57 (32.9%)< 0.01 Necrotizing fasciitis41 (9.9%)9 (5.2%)0.09 Mastoiditis11 (2.6%)1 (0.6%)0.19 Meningitis3 (0.7%)5 (2.9%)0.09 Septic arthritis24 (5.8%)14 (8.1%)0.39 Puerperal infections14 (3.4%)4 (2.3%)0.68 Others26 (6.3%)*9 (5.2%)**0.76 Not known15 (3.6%)8 (4.6%)0.73Respiratory viral coinfections88 (22.6%)15 (9.5%)< 0.001≥ 1 risk factor229 (58.7%)111 (68.5%)0.03Hospital admission378 (96.7%)159 (98.1%)0.35ICU admission110 (28.1%)39 (24.1%)0.32Mortality39 (9.9%)24 (14.8%)0.10Percentages of coinfections, risk factors, hospital admission, ICU admission and mortality are calculated among patients with available informationIR Incidence rate per 100,000 population, ICU Intensive care unit*Includes pharyngitis/tonsillitis with bacteraemia (n = 12), intra-abdominal infection (n = 11), osteomyelitis (n = 2), myositis (n = 1)**Includes pharyngitis/tonsillitis with bacteraemia (n = 5), Intra-abdominal infection (n = 1), osteomyelitis (n = 3) Characteristics and outcomes of patients with laboratory-confirmed invasive group A Streptococcal infection by season. Catalonia, October-2022-October 2024 Percentages of coinfections, risk factors, hospital admission, ICU admission and mortality are calculated among patients with available information IR Incidence rate per 100,000 population, ICU Intensive care unit *Includes pharyngitis/tonsillitis with bacteraemia (n = 12), intra-abdominal infection (n = 11), osteomyelitis (n = 2), myositis (n = 1) **Includes pharyngitis/tonsillitis with bacteraemia (n = 5), Intra-abdominal infection (n = 1), osteomyelitis (n = 3) Respiratory viral coinfections were more frequent in 2022/23 than in 2023/24 (22.6% vs. 9.5%; p < 0.001), whereas the presence of one or more risk factors was higher among iGAS patients diagnosed in 2023/24 (68.5% vs. 58.7%; p = 0.03). There were not significant differences between the two seasons in hospitalization, ICU admission, and mortality. Age group comparison Clinical characteristics and outcomes by age group are presented in Table 2. Among children 0–14 years, empyema was the most frequent clinical manifestation (36.4%) and occurred significantly more often than in adults (6.7%; p < 0.001). In children, although not statistically significant, empyema was more common in 2022/23 than in 2023/24 (39.1% vs. 21.1%, p = 0.21) (Supplementary Material, Table S1). Mastoiditis and meningitis were also more common in children than in adults (7.0% vs. 0.7%, p < 0.001; and 3.9% vs. 0.7%, p = 0.018, respectively). In contrast, adults predominantly presented with skin and soft tissue infections with bacteraemia (29.6% vs. 4.7% in children; p < 0.001), with no significant seasonal variation. Table 2Clinical characteristics and outcomes of patients with laboratory-confirmed invasive group A Streptococcal infections by age group. Catalonia, October-2022-October 2024 0–14 years ≥ 15 years p-valueClinical presentation Empyema47 (36.4%)31 (6.7%)< 0.001 Pneumonia with bacteraemia8 (6.2%)52 (11.3%)0.13 Primary bacteraemia25 (19.4%)100 (21.7%)0.65 Skin and soft tissue infection with bacteraemia6 (4.7%)136 (29.6%)< 0.001 Necrotizing fasciitis6 (4.7%)44 (9.6%)0.11 Mastoiditis9 (7.0%)3 (0.7%)< 0.001 Meningitis5 (3.9%)3 (0.7%)0.018 Septic arthritis8 (6.2%)30 (6.5%)0.94 Puerperal infections0 (0.0%)18 (3.9%)0.046 Other10 (3.3%)25 (5.4%)0.44 Not known5 (3.9%)18 (3.9%)0.81Risk factors ≥ 1 risk factor30 (24.8%)310 (71.9%)< 0.001 Immunosuppression*4 (3.3%)73 (16.9%)< 0.001 Diabetes0 (0.0%)101 (23.4%)< 0.001 Chronic heart disease1 (0.8%)105 (24.4%)< 0.001 Renal failure1 (0.8%)55 (12.8%)< 0.001 Acute or chronic skin lesion4 (3.3%)45 (10.4%)0.015 Pharyngitis or scarlet fever in prior 7 days17 (14.0%)10 (2.3%)< 0.001 Recent surgery or delivery2 (1.7%)18 (4.1%)0.20 Respiratory viral coinfections57 (47.1%)46 (10.8%)< 0.001Outcomes Hospital admission117 (97.5%)420 (97.0%)0.77 ICU admission40 (33.3%)109 (25.2%)0.08 Mortality7 (5.8%)56 (12.9%)0.03Percentages of coinfections, risk factors, hospital admission, ICU admission and mortality are calculated among patients with available informationICU Intensive care unit*Immunosuppression is defined as the presence of active cancer or hematologic malignancy, chronic use of immunosuppressive drugs, long- term corticosteroid therapy or HIV infection Clinical characteristics and outcomes of patients with laboratory-confirmed invasive group A Streptococcal infections by age group. Catalonia, October-2022-October 2024 Percentages of coinfections, risk factors, hospital admission, ICU admission and mortality are calculated among patients with available information ICU Intensive care unit *Immunosuppression is defined as the presence of active cancer or hematologic malignancy, chronic use of immunosuppressive drugs, long- term corticosteroid therapy or HIV infection Overall, 71.9% of adults had one or more risk factors for invasive Streptococcus pyogenes disease, compared with 24.8% of children (p < 0.001). Among children, pharyngitis or scarlet fever in prior 7 days was reported in 14.0% of the cases, significantly more frequently than in adults (2.3%; p < 0.001). In adults, most common risk factors were chronic heart disease (24.4%), diabetes mellitus (23.4%), immunosuppression (16.9%), and chronic kidney disease (12.8%). Respiratory viral coinfections were more frequent in children than in adults (47.1% vs. 10.8%; p < 0.001). Among children, viral respiratory coinfections were more frequent in 2022/23 than in 2023/24 (52.4% vs. 16.7%, p = 0.005), whereas no significant seasonal differences were observed in adults (11.8% vs. 8.6%; p = 0.31) (Supplementary Material, Table S1). The most frequently respiratory virus detected were: influenza A virus (13 cases; 10.7% in children vs. 24; 5.6% in adults; p = 0.07), influenza B virus (15;12.4% vs. 9; 2.1%;; p < 0.001), respiratory syncytial virus (11; 9.1% vs. 5; 1.2%; p < 0.001), adenovirus (13; 10.7% vs. 0, 0.0%; p < 0.001) and rhinovirus/enterovirus (12; 9.9% vs. 1; 0.2%; p < 0.001) (Supplementary Material, Table S2). Outcomes Overall, 97.3% of patients (538/553 with available information) were hospitalized, and among those hospitalized, 27.7% (149/538) required ICU admission. No significant differences were observed in hospitalization or ICU admission percentages between paediatric and adult groups. However, differences in mortality were detected between age groups. Among 556 cases with available outcome data, 63 deaths were reported (11.3%): 56 in adults and 7 in children. Mortality was significantly higher in adults compared to children (12.9% vs. 5.8%; p = 0.034). Of the seven paediatric deaths, five occurred in previously healthy children, one in a child with immunodeficiency, and one in a child with sickle cell disease. Co-infection data were available for six of the seven cases; four had respiratory viral coinfections—two with influenza A, one with influenza B, and one with both respiratory syncytial virus and parainfluenza virus. Among the 56 adults who died, 47 had one or more risk factors, and 11 had respiratory viral coinfections. Factors associated with mortality Univariate analysis identified age, respiratory viral coinfections, presence of at least one risk factor, immunosuppression, chronic heart disease, chronic renal disease and ICU admission as factors significantly associated with mortality (Supplementary Material, Table S3). For the multivariate analysis the variable “≥1 risk factor” was excluded due to collinearity with individual risk factors, which were analysed separately. In the multivariate analysis age (aOR: 1.03; 95% CI: 1.01–1.04), respiratory viral coinfections (aOR: 2.68; 95% CI: 1.09–6.55), chronic renal disease (aOR: 3.15; 95% CI: 1.46–6.80) and ICU admission (aOR: 4.95; 95% CI: 2.54–9.64) remained independently associated with increased mortality risk (Table 3; Supplementary Material, Table S3). Table 3Factors associated with mortality in IGAs patients in multivariate analysisVariablesMultivariate analysisaORCI95%p-valueAge (years)1.031.01–1.040.001Respiratory viral coinfections2.681.09–6.550.031Chronic renal disease3,151.46–6.800.003ICU admission4.952.54–9.64< 0.001aOR adjusted Odds ratio, CI confidence interval, ICU intensive care unitUnivariate comparisons were performed using linear logistic regressionClinical presentations were grouped into three categories (Supplementary Material, Table S3)Independent variables with a p value < 0.20 in univariate analysis were considered for inclusion in the multivariate analysis using linear logistic regression. We excluded the variable “≥1 risk factor” due to collinearity with individual risk factors, which were analysed separatelyStatistical significance (p < 0.05) Factors associated with mortality in IGAs patients in multivariate analysis aOR adjusted Odds ratio, CI confidence interval, ICU intensive care unit Univariate comparisons were performed using linear logistic regression Clinical presentations were grouped into three categories (Supplementary Material, Table S3) Independent variables with a p value < 0.20 in univariate analysis were considered for inclusion in the multivariate analysis using linear logistic regression. We excluded the variable “≥1 risk factor” due to collinearity with individual risk factors, which were analysed separately Statistical significance (p < 0.05) Discussion Following the low incidence of invasive group A streptococcal (iGAS) infections observed during the COVID-19 pandemic, several European countries reported marked increases in late 2022, particularly among children [7–11]. The causes of this resurgence likely include low exposure to Streptococcus pyogenes, especially in children, during pandemic, increased circulation of respiratory virus infections and the potential presence of more virulent clones. Similar post-pandemic surges have also been documented for other invasive bacterial infections [15]. In our study, the incidence rate (IR) of laboratory-confirmed iGAS infections decreased from 5.3 cases per 100,000 population in the 2022/23 season to 2.2 cases per 100,000 in 2023/24, representing a 2.4-fold reduction. In 2022/23 IR was higher in children (0–14 years) than in adults (9.8 vs. 4.6 per 100,000; p < 0.001) and it was especially high in young children. Susceptibility in children may have been amplified in the post-pandemic period, possibly due to reduced immune priming (“immunity debt”). A notable epidemiological shift was observed between seasons. Whereas in 2022/23, IR was higher in children than in adults (9.8 vs. 4.6 cases per 100,000 population), in 2023/24, adults exhibited the highest rates (2.3 vs. 1.7). These findings are consistent with data from the United Kingdom, where the majority of cases in 2023/24 occurred in older adults, contrasting with the unusually high incidence observed in children during 2022/23 [16]. This suggests that the age distribution of cases in 2023/24 may have returned to pre-pandemic epidemiological patterns. Distinct clinical presentation profiles were also observed by age group. Empyema predominated in children, while skin and soft tissue infections with bacteraemia were more frequent in adults. Similar findings have been reported in Norway [11] and Spain where respiratory infections were more common in younger children and non-respiratory infections, such as cellulitis, were more common in adults [17, 18]. Respiratory viral coinfections were more common among iGAS cases in 2022/23 than in 2023/24 (22.6% vs. 9.5%; p < 0.001) and this difference was particularly pronounced among children (52.4% vs. 16.7%; p = 0.005). These results, however, cannot confirm whether viral coinfection plays a causal role in facilitating iGAS or merely reflects temporal association. In England, elevated levels of respiratory virus co-infections were reported in children with iGAS infection during late 2022 [7]. Similarly, in Denmark in 2022–23 there was a 3.6-fold increase of iGAS cases in children with a preceding upper respiratory tract infection compared with pre-COVID-19 seasons [19]. In Catalonia, surveillance data from the Microbiological Reporting System of Catalonia indicate that respiratory virus infections were very low circulating during the COVID19 pandemic but increased in the post-pandemic period, peaking in the 2022/23 season and subsequently declining in 2023/24, particularly among children. The potential contribution of re-emerging viral infections to the 2022/23 iGAS remains unclear. In a study from Poland, analysing data from children with invasive and non-invasive GAS infections, previous or concurrent viral infections were identified as a significant risk factor for developing invasive disease [20]. In the Netherlands, a recent study found that viral infections contributed to the rise in iGAS cases 2022/23 season; however, the re-emergence of these viruses alone did not fully explain the surge, suggesting that additional factors may have played a role [21]. Non-invasive group A streptococcal infections, such as streptococcal pharyngitis, scarlet fever, and impetigo, have been described as risk factors for invasive GAS disease [2]. In Catalonia, the incidence of streptococcal pharyngitis reached 68 cases per 100,000 inhabitants in epidemiological week 23 of the 2022/23 season, compared with a peak of 58 cases per 100,000 in week 42 of 2023/24 [22]. This suggests higher bacterial circulation during the 2022/23 season, coinciding with the peak in invasive GAS cases. The proportion of positive rapid tests for the detection of GAS remained stable across both seasons, indicating no major changes in diagnostic practices or clinical management. Although less pronounced, similar seasonal differences were also observed for impetigo. In our cohort, ICU admission rates were high in both children (33.3%) and adults (25.2%). However, the case fatality rate (CFR) was significantly higher in adults (12.9%) than in children (5.8%; p = 0.034). Comparable mortality rates have been reported in retrospective studies in children. In Germany, the CFR was markedly lower in children (2.0%) than in adults (11.7%) [23], while in France, a CFR of 3.5% was observed among iGAS paediatric cases [24]. In this study mortality was independently associated with age, chronic renal disease, respiratory viral coinfections and ICU admission. Other studies have identified in the multivariate analysis older age, immunosuppression and diabetes [25] and viral co-infections, primarily influenza A [26] as independent factors associated with mortality in adults with iGAS infection. The main strength of this study is the use of a comprehensive, region-wide microbiological surveillance system. The Microbiological Reporting System of Catalonia is a laboratory-based public health surveillance system that collects microbiological data on infectious diseases from all hospital-based and non-hospital microbiology laboratories (public and private) and provides coverage of the entire population of Catalonia. This system enabled the prospective identification of iGAS cases and the subsequent collection of detailed clinical information. In addition, the high proportion of patients with available clinical data enhances reliability and validity of the findings. However, this study has some limitations. First, as iGAS was not a notifiable disease in Catalonia before late 2022, comparable data from earlier seasons are unavailable and we could not compare current findings with pre-pandemic patterns. Following the ECDC and WHO alerts, enhanced epidemiological surveillance of iGAS was implemented at the end of 2022, and this analysis was subsequently extended to the following season. Second, molecular typing of S. pyogenes strains was not performed, limiting assessment of the potential role of specific or more virulent variants. In addition, therapeutic interventions (including antibiotic treatment, pleural drainage, and other supportive measures) were not analysed, although these are important factors influencing patient outcomes. Finally, regarding respiratory viral coinfections, data were collected retrospectively. In some cases it was not possible to determine whether testing had been performed; and therefore, a recorded absence could reflect lack of testing rather than true absence of infection. Moreover, the frequency of testing and the tests used varied across centres; most tests were conducted using multiplex viral panels, which may have different analytical sensitivity compared with single-target tests. In conclusion, a market reduction in iGAS incidence was observed in Catalonia in the 2023/2024 season compared to 2022/23, accompanied by a shift in age-distribution and a lower prevalence of viral co-infections. Distinct clinical presentation between children and adults and higher mortality among adults were evident. Age, chronic renal disease, respiratory viral coinfections and ICU admission were independently associated with mortality. The surge in iGAS cases during the 2022/23 season highlights the need for continued surveillance. Further research is needed to determine the roles of host immunity, viral co-infection and molecular epidemiology in iGAS disease, as well as factors associated with mortality, particularly in paediatric populations. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material Author contributions Marta Martorell: Conception and design of the study, acquisition of data, analysis and interpretation of data; writing and reviewing the article. Aurora Sabria: Conception and design of the study, acquisition of data, analysis and interpretation of data; reviewing the article. Sonia Broner: Conception and design of the study, analysis and interpretation of data; reviewing the article. Pilar Ciruela: Conception and design of the study, acquisition of data, analysis and interpretation of data; writing and reviewing the article. Jacobo Mendioroz: Interpretation of data; reviewing the articled. The rest of authors contributed in proving data, in reviewing the manuscript and approved the version to be submitted. Funding The authors declare that no funds, grants, or other support were received during the preparation of this manuscript. Data availability No datasets were generated or analysed during the current study. Declarations Conflict of interest The authors declare no competing interests. Ethical approval The data presented in this study were obtained as part of regional surveillance through the Microbiological Reporting System of Catalonia, coordinated by the Public Health Agency of Catalonia. Generative AI and AI-assisted technologies in the manuscript preparation process During the preparation of this work, the authors used ChatGPT (OpenAI) only to assist in reviewing and correcting English grammar and syntax. After using this tool/service, the authors reviewed and edited the content as needed and takes full responsibility for the content of the published article. No AI tools were used for content generation of the original draft or data analysis. Footnotes Marta Martorell and Pilar Ciruela contributed equally to this work and share first authorship. References Associated Data Supplementary Materials Supplementary Material Data Availability Statement No datasets were generated or analysed during the current study.